'ition. Specific etiologies have not been identified, but ininiunologic rncchanisrns dmost cer tairily are involvcct. A ~n~i j o r ativanc e has heen the recognition a i i d iiiicter~tariclirig of ctcmyelinating ne~ii op-
' i t k i i o r i~s o c
iated with plasma (ell dysc rasias. Although lewer in riurnber, they are important Ixx < I I I S C the c i r c ulntiiig rrionoclonal protein itself likely dnmage5 iici vc fibers. Under standing the iriec h a n i~n i s involved rnny help clarify the nicc haii5riis of other obscure neuropathies, as well. 1 lie evnluatiori of patients with suspected acute inflammalory dcniyclinating polyneuropathy (AIDI', (;iiillaiii-lSarrk syndrome, GISS), or c hronic inflarnriiatoi y tlernyelinating polyneuropath y (CIDP) iricliitics clct trodiagnostic examination, such as th'it shown in Table I . Ihis examination is dircc tcd tow,ird detec ting evidence of segnierital or rnirltifocal ttcrnyelinatiori. 
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.
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Test most involved site when mild or moderate, least involved if severe.
Evaluate the peroneal motor (extensor digitorum brevis); stimulate ankle, fibular head, and knee. sive weakness, often with bulbar and respiratory iiivolvemeiit; liyporef-lexia or areflexia; slightly diminished sensation; autonomic dysfunction; and cerebrospinal fluid (CSF) protein elevation withAn antecedent event, most commonly a respiratory tract infection or gastroenteritis, is evident within 1 nionth (an average of 15 days) in over (iO% of' ~iatients .~ Other antecedent events include other infections (e.g., hepatitis 13, Epstein--Barr virus, cytornegalovirus, toxoplasmosis), immunizatioii,83 malignant disease, and surgery.5 AIDP also has been associated with acquired HIVl infections, Lyrne disease, Hodgkin's disease, and nonHodgkin's lymphoma. 59 Initial manifestations include syrrinietrical motor and/or sensory syniptorns.4 -I'he niost common complaint is leg weakness,5 and many patierits demonstract spread in a distal-to-proximal fashion. Prominent. facial weakness occurs in about 50% of patient^,^ anti unilateral facial involverrielit tias been described in up to 10% of patients,4 consistent with an isolated mononeuropathy superimposed on a generalized polyneuropathy. Other cranial nerve involvement leads to weakness of mastication, swallowing, and, rarely, eye movements." Despite common sensory symptoms, objective sensory loss is infrequent. ' '' When present, out p]eocytosis."7.48,"8.88."" large myelinated fiber modalities (vibratory and joint position sensations) are involved. Back arid extremity pain are frequent complaints during the early stages of the illness and may be severe.
Autonomic nervous system involvement includes bowel and bladder impairment, cardiac dysrhythmia, labile heart rate and blood pressure resulting in hypertension or hypotension, and impaired thermoregulation."~~ The syndrome of inappropriate antidiuretic hormone secretion (SIADH) has been associated with AIDP, perhaps related to abnormalities of autonomic afferents arising from vascular stretch receptors."8375
The Fisher syndrome is considered a variant of AIDP, consisting of ophthalmoplegia, ataxia, and areflexia.?' I The temporal profile arid CSF h i dings are indistinguishable from AIUP, and electrodiagnostic studies in some patierits show a demyelinating polyneuropathy. 35 Although some consider the syndrome a brainstem encephalitis,"' others") propose peripheral explanations for all of the clinical signs.
The interval from the first neurologic syrnptom to peak impairment is less than 20 days in over 75% of patient^,^ arid 50% of patients reach their nadir by 2 weeks.'" Progression exceeding 4 weeks should be viewed cautiously and alternative diagnoses considered. Diaphragm and intercostal muscle involvement leads to respiratory paralysis in about 30% of patients. Mechanical ventilation usually is initiatcd between 6 and 18 days after onset (mean of 10 days).4 Initial improvement is observed within 40 days in over 80% of the patient^,^ and the overall prognosis is quite good, with most patients demonstratin substantial clinical recovery within G 111ontlis. ~3 'The question of relapse in AIDP is difficult because of potential confusion with other disorders associated with relapsing polyneuropathy, including acute intermittent porphyria,3 systemic lupus erythematosus, and the chronic relapsing forms of inflammatory polyneuropathy . Distinct relapses in patients with otherwise typical AIDP do occur, although the rate is probably less than 5%. In the multicentcred, randomized trial of plasma exchange in the treatment of AIDP,90 four relapses were reported out of 254 patients during the study period. normal but are difficult to elicit. During subsequent examinations, evidence of segmental conduction block and conduction slowing become apparent, with abnormal temporal dispersion of evoked responses, reduced conduction velocity, and prolonged distal latency. ItlenLification of abnormal temporal dispersioii and partial conduction block is the most reliable electrodiagnostic indicator of an acquired demyelinating. folyneuropathy " but not diagnostic of AIIII'.''* A characteristic motor conduction recording fiwn a patient with AIDP is shown in Fig. I . The electrodiagnostic recognition of primary dem yelination is iniprecise and depends upon identifying abnormalities that cannot be explained by axonal involvement alone. This differentiation is most straightforward in acute disorders in previously well individuals without other sources of conduction slowing. Criteria suggestive of acute dernyelination (Table 2) have been modified from those initially proposed by Kelly,@' recognizing that the distinction between "demyelination" and "axonal degeneration" is not always clear.
Evidence of segmental demyelination is present in about 50% of patients during the fjrst 2 weeks of illness. The reduced CMAP amplitude with proximal stiniulation (clavicle) cannot be explained by t.empcml dispersion alone and likely represents partial condiiction block. Early recordings demonstrated progressively decreasing amplitudes, reflecting axonal degeneration or progressive conduction block. During subsequent recordings when the neurologic impairment was unchanged, the evokctl amplitude with distal stimulation improved dramatically. This rapid improvement cannot be explained by axonal regeneration or collateral rcinnervation but is explainable by reversal of distal conduction block.
During the first few weeks of illness, motor abnormalities ar-e much ~iiore cornnion than sensory abnormalities. Motor and sensory evoked amplitudes expressed as ii percentage of the normal mean were averaged for 70 patients with AIDP (34 patients had sequential evaluations) versus time after disease onset and are shown in Fig. 3 Table 3 . During initial evaluation, a common finding was an abnormal median sensory response with normal sural nerve conduc:-tion studies.'9 'I'he median sensory nerve action potential (SNAP) usually was absent or markedly reduced in amplitude with prolonged distal latency. Patients wit.h an abnormal surd and normal median sensory conduction study, a firidirig characteristic of most mild, chronic polyneuropathies. were uncornmon. This finding of a normal, relatively spared sural response in the presence of an abnormal median sensory response, in association with the appropriate clinical syndrome, is chariicteristic of AIDP. Several explanations exist for the discrepancy between motor and sensory studies as well as the discrepancy between the sural and median sensory conduction studies. Neurornuscular transmission failure following a distal axonal lesion would result in reduc-ed CMAP amplit.udes prior to reduc:-tion in SNAP amplitutles. If the aniount of rriyeliri protected the axon or preserved conduction, the larger myelinated sensory fibers would be preferentially preserved relative to the smaller motor fibers. This also could explain prolonged sural nerve function compared to median sensory function, because the sural recording is obtained from the more proxirnal nerve as compared with the terminal median sensory fibers. This distal predilection is consistent wirh reported centripetal derriyelinatiori in sonic patients" and also consistent to--9 -.
8.-
..
-- with the observations of Sumner,H9 who found, using a humorally induced demyelination in rat sciatic nerve, that smaller diameter myelinated fibers were affected earlier and more completely than larger diameter fibers. Nerve roots were highly permeable to antiserum: and distal motor nerve twigs and cummon compression sites were identified as potential areas of vulnerability because of an impaired blood-nerve barrier.
Electromyography (EMG) has a secondary role in evaluating patients with AIDP. Decreased niotor unit action potential (MUAP) recruitment, without evidence of conliguration abnormalities or abnormal spontaneous activity, is the initial finding, reflecting the clinical distribution of weakness. Occasionally, myokymic discharges are observed during the first few weeks of illness.'s They may be found in facial or extremity muscles and may be present in the absence of clinical myokymia. Fibrillation potentials and positive waves appear between 2 and 5 weeks, sirnultarieously in proxiiiial and distal muscles ( random axonal degeneration at any point along the axon or predominant distal involvement. Proximal fibrillation potentials are maximal between 6 and 10 weeks, with distal fibrillation potentials persisting for many months. 'l'he amount of abriorrrial spontaneous activity ranges from none to extensive denerviition with profuse ( 4 t ) positive waves and fibrillation potentials. The early reduction in fibrillation potentials in proximal compai-ed with distal muscles likely reflects reinnervation from axonal sprouting or regeneration in proximal compared with distal muscles. This can be explained both by the greater probability of' regeneration in a short axon and by the increased likelihood of' collateral reinnervation from a greater number of surviving axoris. Nevertheless, some ventilaltor-dcpendent patients recover promptly arid comlpletely, whereas seemingly identical patients havq: a prolonged recovery.
The most powerful predicwr of poor outcome is reduced ChilAP amplitude to less than 10% of the lower limit of nornial.6G Neurologic recovery is positively and significant11 correlat.ed with preserved mean CMAP anipliitude, when the studies are performed between weeks 3 and 5. .I'hese findings support the hypothesis that evidence suggestive of predominant demyelination is correlated with relatively rapid recovery. whereas findings suggestive of severe ;ixonal destruction are correlated with slow rec~very."~'" The amount offibrillation is a relatively poor predictor of prognosis when used alone. 
Additional medical management includes proper bladder care, prompt identification and treatment of superimposed infection, restriction of fluids in patients who are hyponatremic, and antiembolism protection, including low-dose heparin (5000 units subcutaneous twice daily) and antiembolus stockings in quadriparetic patients. Appropriate laboratory studies should be performcd, nionitoring for occult blood loss, anemia and thrombocytopenia, infection, and electrolyte imbalance.
Corticosteroids are of unproven efficacy in AIDP, and their use is corirroversial. The most recent controlled studyg9 reported that prednisone may have slowed the recovery rate and increased the chance of relapse. Anecdotal reports24 exist of single patients who responded dramaLically to sleroids.
The potential importance of humoral factors in the pathogenesis of AIDP suggested that therapeutic plasma exchange (.l'PE) might modify the disease course." The niulticeri~er randomized trial of TPE in the treatment of ,41DP9" dcmonstrate'd significant benefit of TPE when compared with conventional medical treatment, excluding steroids. Hy all criteria, 'L'PE had a beneficial effect. The median time on a respirator was reduced by 1 1 days and the time to unassisted ambulation shortened by an average of 73 days lor respirator-dependent patients who received TPE. Similar-rcsults have tieen reported in two additional controlled, randornized trials. "." Two smaller controlled trials were inconclusivc, although the trends favored the TPE group."'."3 TPE is not effective for all patients. Patient age and the CMAP amplitudes are important predictors of early r e s~~~~i~s i " e , i~s s .~4 TPE appears particularly effect.ive for pat.ien ts w h o begin treatment within 7 days of disease onset, although early, aggressive TPE may be associated with initial improvetrierit followed by relapse, perhaps related to termination of treatment too early in the course of the disease."
CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical Features. CIDP is a chronic progressive or relapsing disorder' of peripheral nerves that c:linic:ally resembles AIDP. Reliable incidence estiniat.es are unavailable, although it is probably less than that of AIDP. Because of the prolonged course, however, I he prevalence probably exceeds t.hat of AIDP. CIDP occurs in both sexes and all ages wilt1 little evidence of peaks other than a predominance in the fifth and sixth decade^.^' Diagnostic criteria differ o n l y slightly for those used for AIDP. At present, the only reliable method for differentiating the two disorders is by an arbitrary clinical judgment regarding the temporal evolution of neurologic symptoms. Patients with CIDP usually have an interval between onset and peak impairment exceeding 4 weeks, and the average duration from onset to peak deficit averages approxiniately 3 months, with a range of 3 weeks to 16 months."
CIDP is characterized by sensory loss and weakness, areflexia, elevated CSF protein, and electrodiagriostic evidence of multifocal demyelination with or without superimposcd axorial degeneration.~5~'fi~''1 'I'he etiology is unknown, but the results of nerve biopsy and reports of response to s t e r o i c~s , '~'~~ a~a t l i i o p r i n e , '~.~~ or suggest an immunologic etiology." TPE": ' ,84,85,92 An identifiable antecedent event is rare compared with AIDP, although CIDP has been associated witti iiniiiune complexes of tiepatitis B virus. 41 Symmetric sensory aridior motor symptoms are the initial manifestation, and weakness usually begins in the legs. Karely, asymmetric findings are present, consistent with rnultifocal demyeliriatirig mononeuropathies.~' Cranial nerve involvenient is common, especially orbicularis oculi weakness, but less prominent than iii AIDP. Maximal weakness usually is distal, and 15 of the 23 patients described by Prineas arid McLeod" were nonambulatoi-y during their most severe episode. Occasional patients require respiratory support, either during an exacerbation or during the terminal phase. Muscle wast.ing may bc severe but often is rnild compared with the degrec and severity of muscle weakness. Sensory symptoms and signs usually are mild but may be associated with a sensory ataxia. All modalities of sensation may be affected." although large fiber loss predominates. Muscle stretch reflexes are usually absent at some time during the illness; rare patients fulfill all other diagnostic criteria but have hypoactive, preserved reflexes. Autonomic involvement is uncommon. The clinical course in CIDP is variable. The term chronic relapsing polyneuropathy (CRP) has been used to describe patients with clear relapses and remissions. Dyck and associates26 estimated that approximately 50% of-patients had a progressive course (slow or stepwise), one-third had a relapsing course, arid the remaining patients experienced a monophasic illness with the peak deficit remaining or developing after 6 months. W-ith current treatments, many patients who may have had progressive disease seemingly respond to treatment but relapse when therapies are tapered or discontinued. The distinction between therapyassociated relapse in CIDP and idiopathic relapse in CRP is unclear.
In CRP, the average interval between relapses is about 10 months, although relapses have been reported 3 1 years after initial attacks. 77 Patients with CRP may remit after many years, without further exacerbations. In early reports of outcome for 53 patients with CIDP who were followed for an average of 7 years, 9 died (6 from the disease), 6 were confined to wheelchair or bed, 36 had a mild to moderately severe impairment, and only 2 had complete resolution.26 Recent experience suggests that more patients experience remission, with fewer patients demonstrating progressive deterioration. This may reflect earlier detection and treatment or recognition of milder cases.
Electtophysiologic Features. The electrodiagnostic findings in CIDP resemble those described late in the course of AIDP and are consistent with multifocal demyelination with variable amounts of superimposed axonal degeneration. The chronic progressive, stepwise progressive, and relapsing forms cannot be differentiated electrophysiologically. Electrodiagnostic criteria suggestive of demyelination in CIDP (' Table 4 ) differ slightly from those described for AIDP. These differences reflect the possible development of axonal stenosis or regeneration, changes that may result in substantial conduction slowing without segmental demyelination. Nevertheless, electrodiagnostic evidence of demyelination is present in virtually all patients with CIDP, and many consider this part of the diagnostic criteria. Motor conduction velocities may be markedly reduced, F response latencies very prolonged (or absent), and temporal dispersion more prominent than observed in AIDP, although individual variations are large. The combination of absent or abnormal SNAPS with normal sural responses occurs but is uncommon in CIDP compared with AIDP. EMG abnormalities are present in most patients with CIDP. Like AIDP, needle examination is useful for defining the chronicity and extent of axonal degeneration.
Treatment. The supportive care of patients with CIDP is identical to that described for AIDP. Unlike AIDP, corticosteroids are of demonstrated benefit in controlled trials of both the CRP and CIDp.8,26,27,77,91 Many prednisone treatment protocols exist, including high-dose daily or alternateday schedules, with slow taper depending upon clinical response. Azathioprine also has been reported to be effective in several case reports and small clinical trials of CIDP patients,94 including patients previously steroid unresponsive or intolerant. Isolated case re orts described TPE as benefiin (;IDp."',5Y,6r84 A consecutive patient trial of TPE demonstrated substantial clinical improvement within 3 weeks in about 50% of progressive CIDP patients." The temporal association between improvement and TYE in patients with 72 Table 4 . Criteria suggestive of dernyelination in the electrodiagnostic evaluation of chronic inflammatory polyneuropathy Evaluation should satisfy at least three of the following in motor nerves (exceptions noted below) 1 Conduction velocity less than 75% of the lower limit of normal (two or more nerves) a 2 Distal latency exceeding 130% of upper limit of normal (two or more nerves) 3 Evidence of unequivocal temporal dispersion or conduction block on proximal stimulation consisting of a proximal-to-distal amplitude ratio less than 0 7 (one or more nerves) 4 F-response latency exceeding 130% of upper limit of normal ( 
DYSPROTElNEMlC OR PARANEOPLASTIC NEUROPATHIES
A subset of patients with acquired dcmyelinating polyneuropathy exists which differs from CIDP only by the presence of an underlying systemic illness. Because the systemic illness may not be apparent when the polyneuropathy is diagnosed, these patients often are classified as having CIDP or even RIDP, although most clinicians restrict these terms lo exclude patients with systemic illness. Included are atients with Waldenstrorn's * n a c r~)~l o~~u I i n e~i i a , '~ ganirria heavy chain disease:" cryoglob~linemia,~~ lymphoma,"' systemic UPU US erythematosus,26 Castleman's disease, l4 and HIV I Acquired demyelinating polyneuro athy rarely can be due to an occult malignancy. '' The polyneuropathy with malignancy can be motor dominant, distal and/or proximal in distribution, evolve rapidly or slowly, and develop a relapsing or remitting course. EMG and pathologic studies are the same as in idiopathic cases. The etiology is assumed to be an irnmunologic process triggered by the underlying malignancy. The association is rare, however, and there is no reason to routinely evaluate all patients for a malignancy. Far more common is the association of an acquired demyelinat.ing polyneuropathy and a plasma cell dyscrasia syndrome. Because of the high prevalence compared with other systemic disorders, these syndromes will be described further below.
Demyelinating Polyneuropathy Encountered in the
Plasma Cell Dyscrasia Syndromes. All idiopathic polyneuropathy patients, anti particularly those with presumed CIDP, should be evaluated for possible occult plasma cell dy~crasias.'~ ' 4 suggested approach is detailed in Table 5 . Up to 10% of patients with idiopathic polyneuropathy harbor Table 5 . Flow chart for evaluation of polyneuropathy patient
Step 1
Ster, 2
Step 3
Step [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 1987 an occult plasma cell dyscrasia which may directly relate to the etiopathogenesis of the neuropathy and respond to treatment. These patients are of investigational importance because the monoclonal protein may cauSe the polyneuropathy. The features of the polyneuropathy in the different plasma cell dyscrasia syndromes are summarized in Table 6 . Primary systemic amyloidosis of the amyloiti light-chain type forms an important subset of the plasma cell dyscrasia syndromes. The polyneuropathy, however, is axonal and usually involves srnall fibers without evidence of conduction slowing, and therefore should not be confused with the dernyelinating dysimniune polynenropathies. Similarly, typical multiple myeloma is associated with a very high monoclonal protein l e~e l , widespread lytic skeletal lesions, anemia, and hypercalcemia. It is rarely associated with p o l y n e u r~p a t h y .~~ When it is, polyneuropathy is heterogeneous in type with little relationship to the status of the niyelotna.
Monoclonal Gammapathy of Undetermined Significance. In evaluating patients with presumed CIDP, a monoclonal gammopathy occasionally is identified. This hematologic disorder, referred to as monoclonal gammopathy of undetermined significance (MCUS), was formerly called "benign monoclonal gammopathy" but was renamed because up to 20% of these patients develop more serious hematologic disease or secondary changes elsewhere, including n e~r o p a t h y .~~ By definition, these patients have a low monoclonal protein concentration (<3 g/dl), no malignant plasma cell infiltration of the bone marrow, and no bony lesions (Table 7 ). This group accounts for about one-half of plasma cell dyscrasia, polyneuropathy patients (Table 8) .
Patients with MGUS-associated neuropathy include IgM and non-IgM types. The IgM group is of int.erest because one-half of these patients have a characteristic polyneuropathy , and the n1ono-clonal immunoglobulin possesses antinerve activity, most commonly directed at an antigen on the Patients with nonreactive IgM neuropathies form a more heterogeneous group. Some closely resemble MAG-reactive polyneuropathies, and some resemble axonal neuropathy. They may reOsteosclerotic Myeloma. Osteosclerotic myeloma differs from typical multiple myeloma. 45 Less than 3% of patients with osteosclerotic myeloma account for about two-thirds of cases of polyneuropathy in large myeloma series; about one-half of all osteosclerotic myeloma patients have a polyneuropathy. Osteosclerotic myeloma is more indolent than multiple myeloma, occurs at a younger age, and is associated with longer survival. The polyneuropathy tends to be slowly progressive, distal, symmetric, and mainly motor, without autonomic dysfunction. CSF protein is very high, and there is frequently papilledema.
Electrodiagnostic findings"343s45 include marked slowing of motor nerve conduction velocities, partial conduction block, and prolonged or absent F-response latencies. SNAPS are decreased or absent. EMG needle examination shows acute and chronic neurogenic changes. Most patients have nionoclonal protein of the lgG or IgA and lambda light-chain type, but occasionally, kappa light-chains are present. There are no reports of direct immunofhorescent staining of nerves from these patients, and the monoclonal protein is not MAG-rea~tive.~' Microinjection of the serum into animal nerves does not cause focal demyelination or conduction
The key to diagnosis is recognition of the monoclonal protein and bony lesions.
The polyneuropathy resembles monophasic CIDP, and consideration of this diagnosis mandates protein studies and a metastatic skeletal survey. Bony lesions occur in the proximal skeleton and may be sclerotic or mixed sclerotic and lytic (Fig. 6) . Biopsy of any suspicious lesion is mandatory. Treatment depends on the nature of the plasmacytoma. If solitary, surgical extirpation or radiation therapy is indicated, and patients improve following effective treatment. Many, or possibly all, eventually relapse. If lesions are multiple, chemotherapy occasionally provides benefit. 21 Some patients' develop widespread findings with polyneuropathy, organomegaly, endocrinop-athy, M protein, and skin changes (POEMS syndrome). This multisystem disorder also has been called "Crow -Fukase syndrome" and "Takatsuki's sy~idrome".'~ None of these terms is satisfactory because they are too restrictive. Most of these patients have monoclonal proteins of the IgG or lgA type with lambda light-chains. One-half to twothirds have osteosclerotic lesions. 'I'he common denominator may be the lambda light-chain or some other secretory product of the plasma cell lesion. Thus, osteosclerotic myeloma may be one end of a spectrum, with POEMS at the other.
'=I CONCLUSION
Patients with acquired demyelinating polyneuropathies comprise a substantial portion of those patients with undiagnosed polyneuropathies presenting for evaluation. -1'heir importance is disproportionate to their numbers, since many are treatable, some are associated with unrecognised systemic disorders, and most provide clues to the etiopathogenesis of other obscure neuropathies. Although their relationship is unclear, the acute, chronic, and dysimmune infiammator y dernyelinating polyneuropathies have characteristic presentations, some of which are easily recognized. Not surprisingly, the electromyographer plays a central role in the evaluation of these patients and is in a position to recognize the patterns of involvement and suggest possible diagnostic alternatives. Thus, the ability to identify an acquired demyelinating polyneuropathy, coupled with a thorough knowledge of these syndromes, is iniportant for any electromyographer who studies neuromuscular patients. trodiagnostic findings for acute, multifocal demyelination. 'I'he model is represented in Figs. 7-9 , consisting of eight axons of variable diameter, ranging from the largest (top) to smallest (bottom). Individual muscle fiber action potentials (MFAPs) are shown to the right of each axon following stimulation of all axons (arrow). Conduction is fastest in the largesl and slowest in the smallest axon; the difference in conduction bctween the largest and smallest fibers constitutes the range of conduction velocities. Individual MFAPs dre summed to obtain a compound muscle action potential (CMAP), shown below the modeled Ilene. In the figures, the simulated CMAP is demonstrated for distal nerve stiniulation (upper half of each figure) and proximal nerve stimulation (lower half of each figure). Latencies could be calculated and a conduction velocity for the fastest axon determined using the distance between stim- ulation sites. In this model of normal nerve (Fig.   7 ), the CMAP amplitude can be iiieasured following proximal and distal stimulation. The reduced CMAP amplitude following proximal stimulation reflects the expected temporal dispersion of individual MFAPs and would be increased if either the distance between stimulation sites or the range of conduction velocities were increased.
Following extensive axorial dcgerieratiori ( tal latency would have been unchanged. The greatest abnormality relative to axonal degeneration would result if only the smallest fiber remained. Both conduction velocity and distal latency would be abnormal, but the magnitude of abnormality would be small compared with the reduced CMAP amplitude.
For comparison, random, multifocal demyelination is denionstrated in Fig. 9 . I n the model, propagation is slowed across a single dernyeliriated node, arid conduction is blocked if two ad-jacent nodes a1-e dcrnyclinated. With distal stimulation, CMAP amplitude is slightly reduc:ctl arid duration slightly increased because of increased dispersion. Dist.al latency is slightly prolonged bec;iuse the largest two fibers are cicm yelinated distally bui. the third largest fiber is intact. Proximal stimulation results in pronounced temporal dispersion of the (;MAP, explained by the variable amounts of demyclination iri some axons cornpared with the others, producing an incrcasc in the range of conduction velocity. ' This results in the initial component of the CMAP (rcpresenting the fastest conduction time) being greatly separated from the trailing portion of the CMAP (representing the slowest conducting axon). l h e CMAP amplitude with proximal stimulation is reduced to a great-er extent than can be explained by temporal dispersion alone, because of conduction block in two of the axons. The likclihood of continuous propagation along the nerve dccreares with increasing iiber length because of thc incrcasctl probability of having dernycliriatiori in two adjacent n o d c x F response latencies would be increased or unobcainablc, depending upon h e extent of conduction block. The findings of abnornral temporal dispersion and partial conduction block are very useful in establishing a diagnosis of acute inllanimalory polyneuropathy. A representative recording from a patient early in the course of inflamrnatory polyneuropathy is shown in Fig. 1 for comparison to the model.
The prescrice of abnormal temporal dispersion is useful in distinguishing acquired demyelinating neuropat hies from hereditary deniyelinating ncuropathie ' I n the latter, demyelination is uniform and involves all fibers. The range of conduction velocity is not dramatically increased, because all fibers demonstrate conduction slowing to a similar exlcrit. 'I'herefore, conduction velocity may be niarkcdly slowed, but abnormal ternporal dispersion does no1 result.
